Racura Oncology Ltd

RAC

Company Profile

  • Business description

    Racura Oncology Ltd is a Phase 3 clinical-stage biopharmaceutical company with a dedicated mission to silence cancer. The company's clinical programs include the Phase 3 EMILI trial in acute myeloid leukaemia, the Phase 1a/b HARNESS trial in combination with osimertinib for EGFR-mutated non-small cell lung cancer, and the Phase 1a/b CPACS trial in combination with doxorubicin, where it aims to deliver both anthracycline cardioprotection and enhanced anticancer activity. The company operated in two segments, being research into an oncology drug, RC220, and the manufacturing and distribution of the drug for clinical trials.

  • Contact

    1 Macquarie Place
    Level 36
    Gateway
    SydneyNSW2000
    AUS

    T: +61 280513043

    https://www.racuraoncology.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    Employees

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,997.30168.10-1.83%
CAC 408,314.2837.72-0.45%
DAX 4026,415.81182.83-0.69%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,811.5570.00-0.64%
HKSE23,508.17245.67-1.03%
NASDAQ24,509.76626.52-2.49%
Nikkei 22558,860.43801.59-1.34%
NZX 50 Index14,306.963.190.02%
S&P 5007,416.59145.08-1.92%
S&P/ASX 2008,883.20161.50-1.79%
SSE Composite Index3,584.5817.99-0.50%

Market Movers